Financhill
Sell
33

DXR Quote, Financials, Valuation and Earnings

Last price:
$8.00
Seasonality move :
5.56%
Day range:
$7.85 - $8.25
52-week range:
$6.55 - $10.00
Dividend yield:
0%
P/E ratio:
25.61x
P/S ratio:
18.44x
P/B ratio:
1.11x
Volume:
3.9K
Avg. volume:
8.5K
1-year change:
-16.59%
Market cap:
$39.7M
Revenue:
$2.1M
EPS (TTM):
-$0.09

Analysts' Opinion

  • Consensus Rating
    Daxor has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $23.50, Daxor has an estimated upside of 192.03% from its current price of $8.05.
  • Price Target Downside
    According to analysts, the lowest downside price target is $22.00 representing 100% downside risk from its current price of $8.05.

Fair Value

  • According to the consensus of 1 analyst, Daxor has 192.03% upside to fair value with a price target of $23.50 per share.

DXR vs. S&P 500

  • Over the past 5 trading days, Daxor has underperformed the S&P 500 by -0.35% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Daxor does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Daxor has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Daxor reported revenues of --.

Earnings Growth

  • Daxor has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Daxor reported earnings per share of --.
Enterprise value:
40.4M
EV / Invested capital:
--
Price / LTM sales:
18.44x
EV / EBIT:
--
EV / Revenue:
18.98x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
1.52%
Net Income Margin (TTM):
25.17%
Return On Equity:
1.57%
Return On Invested Capital:
1.52%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2009-12-31 2010-12-31 2011-12-31 2010-12-31 2011-12-31
Income Statement
Revenue -- -- -- $335.2K $342.6K
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- $0.53 -$0.35
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $29.3K $30.7K $17.2K $14.2K $9.7K
Total Assets $16.6M $25M $30.3M $34.9M $36.6M
Current Liabilities $80K $87.4K $62.4K $103.1K $110.3K
Total Liabilities $877.7K $3.8M $1.3M $858.8K $840.3K
Total Equity $15.7M $21.2M $29M $34M $35.8M
Total Debt $170.7K $3M $1.2M $755.7K $730K
Trailing 12 Months Fiscal Quarters
Period Ending 2009-12-31 2010-12-31 2011-12-31 2010-12-31 2011-12-31
Cash Flow Statement
Cash Flow Operations -- -- -- -$1.8M -$989.9K
Cash From Investing -- -- -- $6.5M -$8.1M
Cash From Financing -- -- -- -$4.7M $9.1M
Free Cash Flow -- -- -- -- --
DXR
Sector
Market Cap
$39.7M
$33.9M
Price % of 52-Week High
80.47%
41.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-16.59%
-46.15%
Beta (5-Year)
-0.059
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $7.71
200-day SMA
Sell
Level $8.55
Bollinger Bands (100)
Sell
Level 7.52 - 8.74
Chaikin Money Flow
Sell
Level -56.8K
20-day SMA
Buy
Level $7.97
Relative Strength Index (RSI14)
Buy
Level 54.76
ADX Line
Buy
Level 19.3
Williams %R
Neutral
Level -48.9589
50-day SMA
Buy
Level $7.75
MACD (12, 26)
Buy
Level 1.62
25-day Aroon Oscillator
Sell
Level -36
On Balance Volume
Neutral
Level 22.5K

Financial Scores

Buy
Altman Z-Score (Annual)
Level (28.1837)
Buy
CA Score (Annual)
Level (1.8224)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-1.4526)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Stock Forecast FAQ

In the current month, DXR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DXR average analyst price target in the past 3 months is $23.50.

  • Where Will Daxor Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Daxor share price will rise to $23.50 per share over the next 12 months.

  • What Do Analysts Say About Daxor?

    Analysts are divided on their view about Daxor share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Daxor is a Sell and believe this share price will drop from its current level to $22.00.

  • What Is Daxor's Price Target?

    The price target for Daxor over the next 1-year time period is forecast to be $23.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is DXR A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Daxor is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of DXR?

    You can purchase shares of Daxor via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Daxor shares.

  • What Is The Daxor Share Price Today?

    Daxor was last trading at $8.00 per share. This represents the most recent stock quote for Daxor. Yesterday, Daxor closed at $8.05 per share.

  • How To Buy Daxor Stock Online?

    In order to purchase Daxor stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Energy Transfer a Good Dividend Stock to Buy Now?
Is Energy Transfer a Good Dividend Stock to Buy Now?

Energy Transfer (NYSE:ET) offers an impressive yield, to say the…

Did the Market Bottom Already?
Did the Market Bottom Already?

The past few weeks have been among the most volatile…

Will NVIDIA Return to Its 52-Week High?
Will NVIDIA Return to Its 52-Week High?

NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…

Stock Ideas

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Sell
50
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
52
RGC alert for Apr 14

Regencell Bioscience Holdings [RGC] is down 11.8% over the past day.

Buy
52
SLP alert for Apr 14

Simulations Plus [SLP] is up 4.69% over the past day.

Sell
38
ZLAB alert for Apr 14

Zai Lab [ZLAB] is up 6.77% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock